- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07784478
Effect of Oxytocin Bolus Versus Slow Infusion on Haemodynamic Stability During Caesarean Section Under Spinal Anaesthesia
Effect of Oxytocin Administration Technique on Haemodynamic Stability During Caesarean Section Under Spinal Anaesthesia: A Randomised Controlled Trial
Study Overview
Status
Intervention / Treatment
Detailed Description
Postpartum haemorrhage remains a leading cause of maternal mortality worldwide. Oxytocin is the first-line uterotonic agent used after delivery of the baby during caesarean section. When given as a rapid intravenous bolus, oxytocin can cause significant hypotension, tachycardia and other haemodynamic changes, especially in women under spinal anaesthesia.
This prospective, randomised, controlled trial will compare the haemodynamic effects of oxytocin 5 IU administered as a rapid intravenous bolus versus the same dose given as a slow intravenous infusion over 15 minutes in women undergoing elective caesarean section under spinal anaesthesia.
Sixty women aged 18-40 years with singleton pregnancy at 37-42 weeks, ASA physical status I or II, will be randomly allocated to one of two groups:
Group A (Bolus): Oxytocin 5 IU given as an intravenous bolus over 15 seconds immediately after umbilical cord clamping.
Group B (Infusion): Oxytocin 5 IU diluted and infused over 15 minutes via syringe pump immediately after umbilical cord clamping.
The primary outcome is the change in systolic blood pressure from baseline at 2, 5 and 10 minutes after oxytocin administration. Secondary outcomes include changes in diastolic blood pressure and heart rate, incidence of hypotension and tachycardia, vasopressor requirements, uterine tone assessed by a 5-point scale, estimated blood loss, and side effects such as nausea, vomiting, flushing and chest discomfort.
The study will be conducted at Hayatabad Medical Complex, Peshawar. All participants will receive standard spinal anaesthesia and routine care. The results are expected to provide local evidence to support safer oxytocin administration practices during caesarean section under spinal anaesthesia.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Fareeha Zahir, MBBS / FCPS-II Trainee
- Phone Number: +923319932275
- Email: fareehak933@gmail.com
Study Locations
-
-
Khyber Pakhtunkhwa
-
Peshawar, Khyber Pakhtunkhwa, Pakistan, 25000
- Hayatabad Medical Complex / Khyber Girls Medical College
-
Contact:
- Fareeha Zahir, MBBS / FCPS-II Trainee
- Phone Number: +923319932275
- Email: fareehak933@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Adult female patients aged 18 to 40 years
- American Society of Anesthesiologists (ASA) physical status class I or II
- Singleton pregnancy at 37 to 42 weeks gestational age
- Scheduled for elective caesarean section under spinal anaesthesia
- Written informed consent obtained
Exclusion Criteria:
- Patients with anticipated hemodynamic instability including severe preeclampsia/eclampsia, placenta previa with active bleeding, placental abruption, or hemorrhagic shock
- Pre-existing cardiovascular disease including ischemic heart disease, valvular heart disease, cardiomyopathy, or arrhythmias
- Baseline systolic blood pressure < 100 mmHg or heart rate > 100 bpm before spinal block
- Known hypersensitivity to oxytocin
- Failed spinal anaesthesia requiring conversion to general anaesthesia
- Patients receiving medications that may alter the hemodynamic response to oxytocin (beta-blockers, calcium channel blockers, ACE inhibitors, or angiotensin receptor blockers)
- Pre-existing anaemia (Hb < 8 g/dL)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Bolus Group
Participants will receive oxytocin 5 IU in 1 mL normal saline as an intravenous bolus over 15 seconds immediately after umbilical cord clamping, followed by 9 mL normal saline infusion over 15 minutes (to maintain blinding).
|
Oxytocin 5 IU administered either as a rapid intravenous bolus over 15 seconds or as a slow intravenous infusion over 15 minutes immediately after umbilical cord clamping during elective caesarean section under spinal anaesthesia.
Other Names:
|
|
Experimental: Infusion Group
Participants will receive oxytocin 5 IU diluted in 50 mL normal saline administered via syringe pump over 15 minutes immediately after umbilical cord clamping.
A simultaneous 1 mL normal saline bolus will be given over 15 seconds to maintain blinding of the initial injection.
|
Oxytocin 5 IU administered either as a rapid intravenous bolus over 15 seconds or as a slow intravenous infusion over 15 minutes immediately after umbilical cord clamping during elective caesarean section under spinal anaesthesia.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Systolic Blood Pressure (SBP) from Baseline
Time Frame: Baseline; 2 minutes, 5 minutes, and 10 minutes after oxytocin administration
|
Change in systolic blood pressure from baseline (mean of three pre-anaesthesia readings) measured at 2, 5, and 10 minutes after oxytocin administration.
|
Baseline; 2 minutes, 5 minutes, and 10 minutes after oxytocin administration
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Diastolic Blood Pressure and Heart Rate from Baseline
Time Frame: 1, 2, 3, 5, 10, 15, and 20 minutes after oxytocin administration
|
Change in diastolic blood pressure and heart rate from baseline at defined time points after oxytocin administration.
|
1, 2, 3, 5, 10, 15, and 20 minutes after oxytocin administration
|
|
Incidence of Clinically Significant Hypotension
Time Frame: Within 20 minutes after oxytocin administration
|
Proportion of participants who develop systolic blood pressure < 90 mmHg or a fall of > 20% from baseline after oxytocin administration.
|
Within 20 minutes after oxytocin administration
|
|
Uterine Contraction Scale Score
Time Frame: 5 minutes after placental delivery
|
Uterine tone assessed by the operating obstetrician using a 5-point scale (Grade 1 = atonic to Grade 5 = very well contracted) at 5 minutes after placental delivery.
Grade 1 or 2 is classified as uterine atony.
|
5 minutes after placental delivery
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Urogenital Diseases
- Vascular Diseases
- Cardiovascular Diseases
- Pathologic Processes
- Female Urogenital Diseases and Pregnancy Complications
- Obstetric Labor Complications
- Pregnancy Complications
- Hemorrhage
- Puerperal Disorders
- Uterine Hemorrhage
- Pathological Conditions, Signs and Symptoms
- Hypotension
- Postpartum Hemorrhage
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Peptide Hormones
- Peptides
- Amino Acids, Peptides, and Proteins
- Pituitary Hormones, Posterior
- Pituitary Hormones
- Oxytocin
Other Study ID Numbers
- CHR-IREB-2026-0050
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.